6-Amino-5-Bromoquinoxaline CAS 50358-63-9 Maʻemaʻe >99.0% (HPLC) Brimonidine Tartrate Intermediate

ʻO 6-Amino-5-Bromoquinoxaline (CAS: 50358-63-9) kahi mea koʻikoʻi waena o nā derivatives quinoxaline.Hoʻohana ʻia ʻo 6-Amino-5-Bromoquinoxaline ma ke ʻano he lāʻau lapaʻau waena, kahi waena o Brimonidine Tartrate (CAS: 70359-46-5).ʻO Brimonidine kahi mea koho α2-receptor blocker, i hoʻomohala maikaʻi ʻia e ka US Company Allergan, kahi lāʻau lapaʻau maka.Hiki iā ia ke hoʻemi i ke kaomi intraocular (IOP).ʻO ka Brimonidine Tartrate ophthalmic solution saling i ka mākeke he ʻano brimonidine tartrate, he lāʻau hoʻohaʻahaʻa IOP maikaʻi no ka glaucoma hāmama ākea a me ka mālama hypertension ocular o nā maʻi, akā no nā pae argon laser IOP.ʻO ka Brimonidine Tartrate ophthalmic solution he ʻano hana ʻelua o ka hana ma o ka hoʻemi ʻana i ka hana hoʻokalakupua wai a me ka hoʻonui ʻana i ka papa puaʻa o ka wai scleral outflow therapeutic kumu.Ma hope o ka hāʻule ʻana i ka maka, wikiwiki ka hopena, a hiki ke piʻi i ka piko i ka wā e hoʻohana ai a hiki i 2h, a hiki i ka manawa kūpono ke mālama i ka 12h.Hiki i ke koko ke ʻike i nā ʻāpana o nā lāʻau lapaʻau.Loaʻa kēia huahana i ka metabolism mua i loko o ke akepaʻa, a hoʻokuʻu ʻia nā metabolites i loko o ka mimi e nā puʻupaʻa.ʻAʻole pili ka systemic absorption a me ka hāʻawi ʻana, a ʻaʻole pono ka poʻe ʻelemakule i ka hoʻoponopono ʻana.ʻO ka Brimonidine Tartrate ophthalmic solution i hoʻohālikelike ʻia me nā α-blockers ʻē aʻe, liʻiliʻi ka momona-soluble, ʻoiai ʻaʻole maʻalahi ke hele i loko o ka pale koko-lolo a ʻaʻole hoʻopuka i ka sedation, hypotension a me nā ʻano like ʻole o ka clonidine central adverse reactions.